Skip to main content
Clinical Trials/IRCT201506201556N77
IRCT201506201556N77
Completed
Phase 2

Duloxetine as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial

Tehran University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
schizophrenia.
Sponsor
Tehran University of Medical Sciences
Enrollment
50
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\-Diagnosis of Schizophrenia based on DSM\-5 criteria; 2\- Age between 18\-60; 3\-Chronic Schizophrenia\- duration of the disorder more than 2 years; 4\-Minimum score of 20 in negative sub score. 5\-being stable on risperidone for the last 2 months Exclusion criteria:1\-Any serious medical or neurological problem; 2\- IQ less than 70; 3\- Substance dependence during the last 6 months(except for nicotine and caffeine); 4\- Score on HDRS less than 14 5\-receiving ECT during the last 3 months ; 6\-Acute or chronic systemic diseases; 7\- History of neurosurgery; 8\- History of head trauma

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials